T-Cell Manufacturing: When Is The Right Time To Automate?
Automation enhances efficiency, reduces manual intervention, and decreases variability while simultaneously minimizing contamination risks and labor costs. Despite the initial investment in automation equipment, the long-term savings can be significant. Integrating automation early in the clinical development pipeline is highly advised to prevent delays and complications. When working with T-cell therapies and controlling variabilities more effectively, turning to automation can also assist in managing production complexities. Explore how integrating artificial intelligence (AI) and machine learning for data analysis can further optimize your manufacturing process. Additionally, this change has the potential to expand the accessibility and benefits of T-cell therapies to a larger patient population.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.